212 related articles for article (PubMed ID: 25962692)
41. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis.
Kawsar HI; Shahnewaz J; Gopalakrishna KV; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2012 Jun; 10(6):370-8. PubMed ID: 22895238
[TBL] [Abstract][Full Text] [Related]
42. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B.
Van Thiel DH; Friedlander L; Kania RJ; Molloy PJ; Hassanein T; Wahlstrom E; Faruki H
Hepatogastroenterology; 1997; 44(15):808-12. PubMed ID: 9222695
[TBL] [Abstract][Full Text] [Related]
43. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
[TBL] [Abstract][Full Text] [Related]
44. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
45. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices.
Tran TT; Rakoski MO; Martin P; Poordad F
Aliment Pharmacol Ther; 2010 Jan; 31(2):240-6. PubMed ID: 19814747
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
47. A cost-consequence analysis of hepatitis B screening in an immigrant population.
Buja A; Martines D; Lobello S; Vinelli A; Bardelle G; Lopatriello S; De Lazzari F; Perrier L; Baldo V
Ann Ist Super Sanita; 2015; 51(4):327-35. PubMed ID: 26783220
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus.
Wang W; Wang J; Dang S; Zhuang G
PeerJ; 2016; 4():e1709. PubMed ID: 27042389
[TBL] [Abstract][Full Text] [Related]
49. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease.
Yarnoff BO; Hoerger TJ; Simpson SK; Leib A; Burrows NR; Shrestha SS; Pavkov ME;
BMC Nephrol; 2017 Mar; 18(1):85. PubMed ID: 28288579
[TBL] [Abstract][Full Text] [Related]
50. A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.
Keshavarz K; Kebriaeezadeh A; Alavian SM; Akbari Sari A; Rezaei Hemami M; Lotfi F; Hashemi Meshkini A; Javanbakht M; Keshvari M; Nikfar S
Hepat Mon; 2016 Sep; 16(9):e37435. PubMed ID: 27822262
[TBL] [Abstract][Full Text] [Related]
51. Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.
Mokhtari AM; Barouni M; Moghadami M; Hassanzadeh J; Dewey RS; Mirahmadizadeh A
Hum Vaccin Immunother; 2021 Jun; 17(6):1825-1833. PubMed ID: 33734949
[TBL] [Abstract][Full Text] [Related]
52. Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.
Tan G; Zhou K; Tan CH; Matchar DB; Farid M; Quek R; Ngeow J
J Glob Oncol; 2016 Aug; 2(4):186-199. PubMed ID: 28717701
[TBL] [Abstract][Full Text] [Related]
53. [Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 22 September 2017].
Horváth G; Gerlei Z; Gervain J; Lengyel G; Makara M; Pár A; Rókusz L; Szalay F; Tornai I; Werling K; Hunyady B
Orv Hetil; 2018 Feb; 159(Suppl 1):24-37. PubMed ID: 29478340
[TBL] [Abstract][Full Text] [Related]
54. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
[TBL] [Abstract][Full Text] [Related]
55. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa.
Béguelin C; Fall F; Seydi M; Wandeler G
Expert Rev Gastroenterol Hepatol; 2018 Jun; 12(6):537-546. PubMed ID: 29737218
[TBL] [Abstract][Full Text] [Related]
56. Liver toxicity of chemotherapy and targeted therapy for breast cancer patients with hepatitis virus infection.
Liu Y; Li ZY; Li X; Wang JN; Huang QA; Huang Y
Breast; 2017 Oct; 35():191-195. PubMed ID: 28800545
[TBL] [Abstract][Full Text] [Related]
57. A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
Bunyoz KI; Krarup H; Weis N
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260595
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience.
Kim MK; Ahn JH; Kim SB; Im YS; Lee SI; Ahn SH; Son BH; Gong G; Kim HH; Kim WK
Korean J Intern Med; 2007 Dec; 22(4):237-43. PubMed ID: 18309681
[TBL] [Abstract][Full Text] [Related]
59. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.
Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N
BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894
[TBL] [Abstract][Full Text] [Related]
60. The cost-effectiveness of screening for chronic hepatitis B infection in the United States.
Eckman MH; Kaiser TE; Sherman KE
Clin Infect Dis; 2011 Jun; 52(11):1294-306. PubMed ID: 21540206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
